# The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06115499/  
OnCo record `nct06115499` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of nab-paclitaxel, gemcitabine and cisplatin in pancreatic cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.

## Summary

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer is a phase 2/3, randomised interventional study registered as NCT06115499 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 10 participants, started 2024-08-13 and due to reach its primary completion in 2029-01-15. Interventions recorded: Nab paclitaxel; Gemcitabine; Cisplatin; Magnetic Resonance Imaging; Computed Tomography; Biospecimen Collection. Conditions listed: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Squamous Cell Carcinoma; Stage IV Pancreatic Cancer AJCC v8. Primary outcome: Overall response rate (ORR) (Phase II); Overall Survival (OS) (Phase III). Pancreatic eligibility wording from the registry: "* Metastatic pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06115499
- Phase: 2/3
- Setting: Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
- Sponsor: Alliance for Clinical Trials in Oncology
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT06115499: https://clinicaltrials.gov/study/NCT06115499

## Connected records

- cancers: [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06115499.json